Global Epistaxis Treatment Market, By Type (Anterior, Posterior), Treatment (Topical Vasoconstrictors, Chemical Cautery, Electrocautery, Nasal Tampon, Foley Catheter, Arterial Ligation), Route of Administration (Oral, Parenteral, Topical, Others), End-Users (Clinics, Hospitals, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Market Analysis and Insights: Global Epistaxis Treatment Market
Epistaxis treatment market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market is growing at a CAGR of 5.30% in the above-mentioned research forecast period. Increasing patient population relying on anticoagulant medications and rising cases of infection, allergies, snorting, hypertension among others.
Growing patient population with inherited bleeding characters and technological advancements also boost up the market growth. Moreover, vigorous research and development efforts and rising healthcare expenditure act as opportunity for the market growth. But, sometimes adverse effect related to the drugs, high cost of devices and stringent regulations may hamper the global epistaxis treatment market.
Epistaxis results in uncertain nose bleeding from both of the nostrils. Based on the site of bleeding originates epistaxis is classified under anterior and posterior epistaxis. Epistaxis (nosebleed) can be controlled up to a level at home but in severe conditions it became quite difficult to manage such condition which demands the appropriate treatment and novel devices. This has been reported that approximately 60% of worldwide population has one time epistaxis in their life time. Among the two types of epistaxis anterior type is most common among children and can be treated at home setting while posterior epistaxis needs specific medical treatment. Epistaxis can be treated by application of topical vasoconstrictors, chemical cautery, electrocautery, foley catheter among others.
As per the publication of NCBI this has been reported that epistaxis is highly prevalent worldwide and accounts for 2.4 million death in U.S. Moreover 60% of population experiences epistaxis once in life. This affected patient population thus relies on effective treatment approach and hence expected to provide market with the lucrative growth.
This epistaxis treatment market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Global Epistaxis Treatment Market Scope and Market Size
Epistaxis treatment market is segmented on the basis of type, treatment, route of administration, end-users and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of type, the epistaxis treatment market is segmented into anterior and posterior.
- On the basis of treatment, the epistaxis treatment market is segmented into topical vasoconstrictors, chemical cautery, electrocautery, foley catheter, and arterial ligation or embolization. The topical vasoconstrictors segment in further sub- segmented into stimulants, amphetamines, and antihistamines. Amphetamines is sub-segmented into ritalin, concerta (methylphenidate), adderall, ephedrine. Antihistamines is further sub-segmented into chlorphenamine, hydroxyzine and promethazine, cetirizine, fexofenadine and loratadine.
- On the basis of route of administration, the epistaxis treatment market is segmented into oral, parenteral, topical others.
- On the basis of end-users, the epistaxis treatment market is segmented into clinics, hospitals, homecare, others.
- On the basis of distribution channel, the epistaxis treatment market has also been segmented into hospital pharmacy, retail pharmacy, online pharmacy, others.
Epistaxis Treatment Market Country Level Analysis
Epistaxis treatment market is analysed and market size information is provided by country, type, treatment, route of administration, end-users and distribution channel as referenced above.
The countries covered in the epistaxis treatment market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.
On geographical estimation, North America accounts the largest market share due to rising blood disorders, growing incidence of nasal and paranasal sinus cancers in U.S and Canada. Europe accounts the second largest market share due to changing environmental conditions and increasing collaboration and partnership for development of novel therapies. Asia-Pacific is expected to account for the largest market share over coming years for the epistaxis treatment market due to increasing demand of effective treatment approaches and increasing investment for boosting up the drug manufacturing facilities.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Epistaxis treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Epistaxis Treatment Market Share Analysis
Epistaxis treatment market competitive landscape provides details by competitor, details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to epistaxis treatment market.
The major players covered in the epistaxis treatment market are Novartis AG, Noramco, Mallinckrodt, Johnson & Johnson Health Care Systems Inc., Teva Pharmaceuticals USA, Inc., Camber Pharmaceuticals, Inc., Amneal Pharmaceuticals LLC, Lannett, Takeda Pharmaceutical Company Limited, Zydus Cadila, Par Pharmaceutical, Aurobindo Pharma USA, AdvaCare Pharma, Pfizer Inc., Angiplast, Sterimed Group, Cardinal Health, Elanor Surgicals, hitecmed, B.F. ASCHER & CO., INC., Bayer, Smith & Nephew among other domestic and global players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
SKU-
